|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Voltaggio L, Cimino-Mathews A, Bishop JA,
Argani P, Cuda JD, Epstein JI, Hruban RH, Netto GJ, Stoler MH,
Taube JM, et al: Current concepts in the diagnosis and pathobiology
of intraepithelial neoplasia: A review by organ system. CA Cancer J
Clin. 66:408–436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berghmans T, Pasleau F, Paesmans M,
Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts
S, Lafitte JJ, et al: Surrogate markers predicting overall survival
for lung cancer: ELCWP recommendations. Eur Respir J. 39:9–28.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cufer T and Knez L: Update on systemic
therapy of advanced non-small-cell lung cancer. Expert Rev
Anticancer Ther. 14:1189–1203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Domingues D, Turner A, Silva MD, Marques
DS, Mellidez JC, Wannesson L, Mountzios G and de Mello RA:
Immunotherapy and lung cancer: Current developments and novel
targeted therapies. Immunotherapy. 6:1221–1235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Casaluce F, Sgambato A, Sacco PC,
Palazzolo G, Maione P, Rossi A, Ciardiello F and Gridelli C:
Emerging drugs targeting PD-1 and PD-L1: Reality or hope? Expert
Opin Emerg Drugs. 19:557–569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li CM, Chu WY, Wong DL, Tsang HF, Tsui NB,
Chan CM, Xue VW, Siu PM, Yung BY, Chan LW and Wong SC: Current and
future molecular diagnostics in non-small-cell lung cancer. Expert
Rev Mol Diagn. 15:1061–1074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Slezak-Prochazka I, Durmus S, Kroesen BJ
and van den Berg A: MicroRNAs, macrocontrol: Regulation of miRNA
processing. RNA. 16:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eder M and Scherr M: MicroRNA and lung
cancer. N Engl J Med. 352:2446–2448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jazdzewski K, Murray EL, Franssila K,
Jarzab B, Schoenberg DR and de la Chapelle A: Common SNP in
pre-miR-146a decreases mature miR expression and predisposes to
papillary thyroid carcinoma. Proc Natl Acad Sci USA. 105:7269–7274.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vinci S, Gelmini S, Pratesi N, Conti S,
Malentacchi F, Simi L, Pazzagli M and Orlando C: Genetic variants
in miR-146a, miR-149, miR-196a2, miR-499 and their influence on
relative expression in lung cancers. Clin Chem Lab Med.
49:2073–2080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li YL, Wang J, Zhang CY, Shen YQ, Wang HM,
Ding L, Gu YC, Lou JT, Zhao XT, Ma ZL and Jin YX: miR-146a-5p
inhibits cell proliferation and cell cycle progression in NSCLC
cell lines by targeting CCND1 and CCND2. Oncotarget. 7:59287–59298.
2016.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang W and Kong L, Ni Q, Lu Y, Ding W,
Liu G, Pu L, Tang W and Kong L: miR-146a ameliorates liver
ischemia/reperfusion injury by suppressing IRAK1 and TRAF6. PLoS
One. 9:e1015302014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Santra M, Zhang ZG, Yang J, Santra S,
Chopp M and Morris DC: Thymosin β4 up-regulation of microRNA-146a
promotes oligodendrocyte differentiation and suppression of the
Toll-like proinflammatory pathway. J Biol Chem. 289:19508–19518.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Selvamani SP, Mishra R and Singh SK:
Chikungunya virus exploits miR-146a to regulate NF-κB pathway in
human synovial fibroblasts. PLoS One. 9:e1036242014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zochbauer-Muller S, Gazdar AF and Minna
JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol.
64:681–708. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Makeyev EV and Maniatis T: Multilevel
regulation of gene expression by microRNAs. Science. 319:1789–1790.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van Den Berg A, Mols J and Han J:
RISC-target interaction: Cleavage and translational suppression.
Biochim Biophys Acta. 1779:668–677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dillhoff M, Wojcik SE and Bloomston M:
MicroRNAs in solid tumors. J Surg Res. 154:349–354. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vychytilova-Faltejskova P and Slaby O:
Circulating blood-borne microRNAs as biomarkers in solid tumors.
Exp Suppl. 106:75–122. 2015.PubMed/NCBI
|
|
24
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinez P, Martinez-Marti A, Navarro A,
Cedres S and Felip E: Molecular targeted therapy for early-stage
non-small-cell lung cancer: Will it increase the cure rate? Lung
cancer. 84:97–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zavala V, Perez-Moreno E, Tapia T, Camus M
and Carvallo P: miR-146a and miR-638 in BRCA1-deficient triple
negative breast cancer tumors, as potential biomarkers for improved
overall survival. Cancer Biomark. 16:99–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tomokuni A, Eguchi H, Tomimaru Y, Wada H,
Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Nagano H, Mori M
and Doki Y: miR-146a suppresses the sensitivity to interferon-alpha
in hepatocellular carcinoma cells. Biochem Biophys Res Commun.
414:675–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kao YY, Tu HF, Kao SY, Chang KW and Lin
SC: The increase of oncogenic miRNA expression in tongue
carcinogenesis of a mouse model. Oral Oncol. 51:1103–1112. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu R, Yi B, Wei S, Yang WH, Hart KM,
Chauhan P, Zhang W, Mao X, Liu X, Liu CG and Wang L:
FOXP3-miR-146-NF-κB axis and therapy for precancerous lesions in
prostate. Cancer Res. 75:1714–1724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiang W, Wu X, Huang C, Wang M, Zhao X,
Luo G, Li Y, Jiang G, Xiao X and Zeng F: PTTG1 regulated by
miR-146a-3p promotes bladder cancer migration, invasion, metastasis
and growth. Oncotarget. 8:664–678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma W, Zhao X, Liang L, Wang G, Li Y, Miao
X and Zhao Y: miR-146a and miR-146b promote proliferation,
migration and invasion of follicular thyroid carcinoma via
inhibition of ST8SIA4. Oncotarget. 8:28028–28041. 2017.PubMed/NCBI
|
|
33
|
Zhang X, Li D, Li M, Ye M, Ding L, Cai H,
Fu D and Lv Z: MicroRNA-146a targets PRKCE to modulate papillary
thyroid tumor development. Int J Cancer. 134:257–267. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hung PS, Liu CJ, Chou CS, Kao SY, Yang CC,
Chang KW, Chiu TH and Lin SC: miR-146a enhances the oncogenicity of
oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and
NUMB genes. PLoS One. 8:e799262013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saba R, Sorensen DL and Booth SA:
MicroRNA-146a: A dominant, negative regulator of the innate immune
response. Front Immunol. 5:5782014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang RJ, Zheng YH, Wang P and Zhang JZ:
Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in
non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771.
2015.PubMed/NCBI
|
|
37
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Greve J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang WM and Liu JC: Effect and molecular
mechanism of mir-146a on proliferation of lung cancer cells by
targeting and regulating MIF gene. Asian Pac J Trop Med. 9:806–811.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thomson DW, Bracken CP and Goodall GJ:
Experimental strategies for microRNA target identification. Nucleic
Acids Res. 39:6845–6853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Vandenboom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garcia AI, Buisson M, Bertrand P, Rimokh
R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I and Mazoyer S:
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in
triple negative sporadic breast cancers. EMBO Mol Med. 3:279–290.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Forloni M, Dogra SK, Dong Y, Conte D Jr,
Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR and Wajapeyee N:
miR-146a promotes the initiation and progression of melanoma by
activating Notch signaling. Elife. 3:e014602014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cornett AL and Lutz CS: Regulation of
COX-2 expression by miR-146a in lung cancer cells. RNA.
20:1419–1430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Taganov KD, Boldin MP, Chang KJ and
Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an
inhibitor targeted to signaling proteins of innate immune
responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Labbaye C and Testa U: The emerging role
of MIR-146A in the control of hematopoiesis, immune function and
cancer. J Hematol Oncol. 5:132012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park H, Huang X, Lu C, Cairo MS and Zhou
X: MicroRNA-146a and microRNA-146b regulate human dendritic cell
apoptosis and cytokine production by targeting TRAF6 and IRAK1
proteins. J Biol Chem. 290:2831–2841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yousefzadeh N, Alipour MR and Soufi FG:
Deregulation of NF-κB-miR-146a negative feedback loop may be
involved in the pathogenesis of diabetic neuropathy. J Physiol
Biochem. 71:51–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
